Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tyra Bioscience ( (TYRA) ) just unveiled an update.
On April 16, 2026, Tyra Biosciences’ board of directors expanded its size from nine to ten members and appointed industry veteran Habib J. Dable as a Class II director, with an initial term ending at the 2026 annual shareholder meeting. The board determined that Dable, who brings extensive experience from senior roles at Acceleron Pharma and Bayer, qualifies as an independent director under Nasdaq rules.
Dable currently advises RA Capital Management and serves on several biopharmaceutical boards, adding deep sector and governance expertise to Tyra’s leadership. In connection with his appointment, he received a standard non-employee director equity grant of options to purchase 44,400 shares vesting over three years, along with customary cash compensation and an indemnification agreement, underscoring Tyra’s adherence to market-standard board compensation and governance practices.
The most recent analyst rating on (TYRA) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Tyra Bioscience stock, see the TYRA Stock Forecast page.
Spark’s Take on TYRA Stock
According to Spark, TipRanks’ AI Analyst, TYRA is a Neutral.
The score is held back primarily by weak financial performance (no revenue, widening losses, and increasing cash burn), partially offset by strong technical momentum (price above major moving averages with positive MACD) and supportive corporate events (notably the $126M equity raise). Valuation remains difficult to assess due to negative earnings and no dividend data.
To see Spark’s full report on TYRA stock, click here.
More about Tyra Bioscience
Tyra Biosciences, Inc. is a biotechnology company operating in the biopharmaceutical sector, focused on developing targeted therapies. The company’s leadership and board composition are important to its strategic direction and ability to execute in a competitive life sciences market.
Average Trading Volume: 1,038,754
Technical Sentiment Signal: Buy
Current Market Cap: $1.88B
Learn more about TYRA stock on TipRanks’ Stock Analysis page.